Key result
PCSK9 blocks SNX17-mediated LDLR recycling, explaining PCSK9 inhibitor resistance in specific FH variants.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our study resolves the longstanding question of how PCSK9 promotes LDLR degradation, and supports the need for genetic diagnosis and the consideration of alternative therapies independent of LDLR for patients who are not responsive to PCSK9-based drugs.”
“Guan et al. showed that acidic pH induces conformational changes in the extracellular domain of LDLR, promoting its interaction with sorting nexin 17 (SNX17) via the NPxY motif in LDLR's intracellular domain. This interaction is essential for LDLR recycling. Knockdown of SNX17 promotes LDLR lysosomal degradation. Importantly, PCSK9 disrupts the LDLR-SNX17 interaction by preventing the pH-induced conformational change in the extracellular domain of the receptor, ultimately rerouting LDLR to lysosomes. Knockdown of SNX17 impairs PCSK9-promoted LDLR degradation. Furthermore, Guan et al. observed that individuals with familial hypercholesterolemia (FH) carrying mutations that impair LDLR recycling exhibit resistance to PCSK9 inhibitors, underscoring the clinical relevance of these findings.”
PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling, providing a mechanistic explanation for why patients with specific FH sequence variations are resistant to PCSK9 inhibitors.
BACKGROUND: Low-density lipoprotein (LDL) is internalized into cells mainly through LDLR (LDL receptor)–mediated endocytosis. In an acidic endosome, LDLR is released from LDL and recycles back to the cell surface, whereas LDL is left in the endosome and degraded in the lysosome. Circulating PCSK9 (proprotein convertase subtilisin/kexin 9) binds with LDLR and is internalized into the endosome, similar to LDL. In an acidic endosome, LDLR fails to disassociate from PCSK9, and both proteins are degraded in the lysosome. PCSK9 inhibitors are widely used for treating hypercholesterolemia. However, how PCSK9 diverts LDLR to the lysosome for degradation remains elusive. Some patients are resistant to PCSK9 inhibitors, for unknown reasons. METHODS: Both in vitro and in vivo approaches were used to investigate the molecular and cellular mechanisms of PCSK9-mediated LDLR degradation. LDLR containing FH sequence variations was expressed in Ldlr knockout mice and knockout HuH7 cells to evaluate their response to PCSK9 and PCSK9 inhibitors. RESULTS: Acidic pH induces a conformational change in LDLR extracellular domain and promotes its interaction with SNX17 (sorting nexin 17) through the intracellular domain. Knocking down SNX17 abolishes LDLR recycling and causes accelerated degradation in the lysosome. PCSK9 prevents the acidic pH–induced conformational change in LDLR and blocks its interaction with SNX17. Knocking down SNX17 abolishes PCSK9-mediated LDLR degradation. Any FH sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors, even though they can internalize LDL. CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in FH leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2025) studied hypercholesterolemia. PCSK9 was evaluated on LDLR degradation and recycling. PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling, explaining why patients with FH sequence variations disrupting LDLR recycling are resistant to PCSK9 inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: